Home › Activist investors › Camac Fund, LP
Dissident not on the roster. Positions and campaigns from Camac Fund, LP’s SEC filings. Updated November 20, 2026.
No active campaign by this definition (see How to read this).
No current position by this definition.
Campaigns are compiled from SEC filings (13D, proxy contest filings and settlement 8-Ks); campaigns run without SEC filings, e.g. by public letter below the 5% threshold, may not appear.
| Company | Outcome or last status | Date | First filing | Highest stage | Filings | Meeting / votes |
|---|---|---|---|---|---|---|
| Forte Biosciences, Inc.Board seats | Contested vote held — 0 of 2 of the activist's nominees elected | Sep 19, 2023 | May 25, 2023 | Proxy contest filed | latest (8) | how managers voted |
Fund votes come from Form N-PX filings, which this site holds from July 1, 2023 (meetings through June 30, 2026; later meetings appear when the managers file their next N-PX); earlier contests and campaigns that settled before a vote are listed under the activist’s campaigns.
Contested director elections at which Camac Fund, LP had nominees on the ballot, from the managers’ N-PX vote reports and the company’s Form 8-K (Item 5.07) results. A manager “backed” a side when most of its funds’ votes on that side’s nominees were FOR; with a universal proxy card a fund can vote for nominees of both sides, so the counts are shown too.
| Manager | Backed the activist | Forte Biosciences, Inc. 2023 |
|---|---|---|
| Vanguard | 0 of 1 (0%) | Company |
| Fidelity | 0 of 1 (0%) | Split |
| BlackRock | 0 of 1 (0%) | Company |
| Blackstone Alternative Investment Funds | 0 of 1 (0%) | Split |
| Guggenheim | 0 of 1 (0%) | Split |
— = no N-PX votes on the contested director elections found for that manager.
Result: Form 8-K, Item 5.07. Activist’s nominees: Chris McIntyre (not elected (8-k tally)); Michael G. Hacke (not elected (8-k tally)). Company’s nominees: Lawrence Eichenfield, M.D. (elected (8-k tally)); Paul A. Wagner, Ph.D. (elected (8-k tally)).
| Manager | Stance | FOR the activist’s nominees | Avg. shares FOR each activist nominee | FOR the company’s nominees |
|---|---|---|---|---|
| Vanguard | Backed the company's nominees | 0 of 6 fund votes | 0 | 6 of 6 fund votes |
| Fidelity | Split | 4 of 8 fund votes | 100,798 | 0 of 4 fund votes |
| BlackRock | Backed the company's nominees | 0 of 2 fund votes | 0 | 2 of 2 fund votes |
| Blackstone Alternative Investment Funds | Split | 1 of 2 fund votes | 400 | 0 of 1 fund votes |
| Guggenheim | Split | 1 of 2 fund votes | 34 | 0 of 1 fund votes |
Source: N-PX reports filed by 5 managers for the meeting of Sep 19, 2023; a nominee’s side is read from how most filers labelled the ballot item (two or more filers, 70% agreeing).
How each campaign on record ended, as read from the filings: settlements disclosed in the company’s 8-K or the investor’s 13D, contested votes (8-K Item 5.07), withdrawals and 13D amendments below 5%.
| Company | Outcome | Detail | Date | First filing |
|---|---|---|---|---|
| Forte Biosciences, Inc. | Contest vote: nominees not elected | 0 of 2 of the activist's nominees elected | Sep 19, 2023 | May 25, 2023 |
The change in the company’s closing share price from the first trading day on or before the investor’s first Schedule 13D to the latest close, and to 6 and 12 months after it, beside the S&P 500 (SPY) over the same dates. This is a price change after a filing date: it is not attributed to the investor, and it is not the investor’s return. Coverage: 0 of 0 13D positions have prices (the site’s daily price history starts November 10, 2025, and covers only listed tickers it tracks).